Background More studies are required on the ocular manifestations of coronavirus disease 2019 (COVID-19) to help guide ophthalmologists to carefully screen these patients for early diagnosis, so that prompt management can be done to prevent further damage. Aim The aim of this study was to evaluate the ocular findings among patients with COVID-19 at a tertiary care center. Patients and methods A hospital record-based retrospective study was carried out on 1036 patients diagnosed with COVID-19 at a tertiary care center in Western Maharashtra, India. Visual acuity was measured at bedside by the finger-counting method or by using the Snellen's chart, if required. Anterior-segment eye examination was done on torchlight and binocular corneal loops, and slit-lamp biomicroscopy, as required. Extraocular movements were recorded in all nine gazes. Indirect ophthalmoscopy was done under full mydriasis. Results The age of the patients ranged from 4 to 98 years with a mean of 45.6±16.24 years. The majority (22.5%) of the patients belonged to the age group of 30–39 years. Males (61.8%) were more than females (38.2%). The ocular findings included congestion (16.8%), continuous conjunctival congestion (5.3%), vasculitic retinal-vein occlusion (8.7%), combined central retinal artery and vein occlusion (1.4%), central retinal-artery occlusion (0.8%), convergence insufficiency (8.4%), and lateral rectus paresis (3.5%). Sex was not associated with abnormal ocular findings (P>0.05). On the other hand, advanced age was a significant risk factor for ocular manifestations of COVID-19 (P<0.05). Only the abnormal ocular findings of the anterior segment were found to be associated with longer duration of hospital stay. Conclusions Elderly people were more likely to develop ocular manifestations of COVID-19 compared with their younger counterparts, irrespective of gender. A significant proportion of infected people developed ocular manifestations of COVID-19.
BACKGROUND Orbital tumour, benign or malignant, comprises of a fair number of patients presenting in hospitals with a mass lesion or proptosis. Its early diagnosis and treatment is necessary especially in malignant cases even it can save patient's life. MATERIALS AND METHODS We have recruited the patients presenting in our oculoplasty OPD in RIO with orbital mass lesion or any patient who has symptoms suggestive of orbital mass lesion after applying inclusion and exclusion criteria. Clinical and radiological diagnosis has been made and diagnostic/therapeutic surgical procedures have been performed in order to reach a histopathological diagnosis. Then, excel data sheet is prepared and statistical analysis done.
BACKGROUND To compare corneal endothelial cell count (ECC) after one-step surgery: combined phacoemulsification-IOL and pars planavitrectomy (PPV) with that after two-step surgery-PPV followed by phacoemulsification-IOL after at least 2 months of the first procedure. Purpose-After reviewing the available literature, we did not find studies on the above stated topic. This study may prove helpful to the surgeon in considering one-step combined phacoemulsification-IOL and pars planavitrectomy for the patient. MATERIALS AND METHODS 62 patients (65 eyes) who underwent one-step phacovitrectomy (33 eyes of 32 patients; group 1) and two-step surgery-PPV followed by phacoemulsification-IOL (32 eyes of 30 patients; group 2) were enrolled in this study. The Corneal endothelial cell count of both the groups were compared with the baseline values of the respective groups at the end of 3months and 6 months after surgery and cell count of both the groups were compared. RESULTS The mean endothelial cell loss in group 2 (22.67%±19.49% and 23.82%±18.96% at 3 and 6 months respectively) was significantly higher than that in group 1 (16.1%±9.62% and 15.08%±11.24% at 3 and 6 months respectively) [p=0.0024 and p=0.0022 at 3 months and 6 months respectively]. CONCLUSION Corneal endothelial cell loss was found more in Group-2 patients; may be due to complications following first surgery and due to more tissue handling.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.